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Abstract
Infestation with Varroa spp. (varroosis) has been assessed according to the criteria of the Animal
Health Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the
eligibility of varroosis to be listed, Article 9 for the categorisation of varroosis according to disease
prevention and control rules as in Annex IV and Article 8 on the list of animal species related to
varroosis. The assessment has been performed following a methodology composed of information
collection and compilation, expert judgement on each criterion at individual and, if no consensus was
reached before, also at collective level. The output is composed of the categorical answer, and for the
questions where no consensus was reached, the different supporting views are reported. Details on
the methodology used for this assessment are explained in a separate opinion. According to the
assessment performed, it is inconclusive whether varroosis can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL because there was no full consensus on the
criterion 5 A(v). Consequently, the assessment on compliance of varroosis with the criteria as in Annex
IV to the AHL, for the application of the disease prevention and control rules referred to in Article 9(1),
and which animal species can be considered to be listed for varroosis according to Article 8(3) are also
inconclusive.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of
Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework (EFSA
AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc
methodology followed for the assessment of the disease to be listed and categorised according to the
criteria of Article 5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW
Panel, 2017).
The present document reports the results of assessment on infestation with Varroa spp. (varroosis)
according to the criteria of the AHL articles as follows:
• Article 7: varroosis proﬁle and impacts
• Article 5: eligibility of varroosis to be listed
• Article 9: categorisation of varroosis according to disease prevention and control rules as in
Annex IV
• Article 8: list of animal species related to varroosis.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of infestation with Varroa spp. (varroosis) according to the
Article 7 criteria of the AHL and related parameters (see Table 2 of the opinion on methodology (EFSA
AHAW Panel, 2017)), based on the information contained in the fact-sheet as drafted by the selected
disease scientist (see Section 2.1 of the scientiﬁc opinion on the ad hoc methodology) and amended
by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
There are four species in the genus Varroa (Parasitiformes; Varroidae): V. destructor, V. jacobsoni,
V. underwoodi and V. rindereri. The disease known as Varroosis is caused by Varroa destructor,1 which
is an ectoparasitic honey bee mite that has successfully shifted from the original host, Apis cerana, to
the Western honey bee, Apis mellifera, which the present document mainly refers to. It is not
surprising that the new host lacks features of a stable and relatively harmless host–parasite
relationship as in Apis cerana which has developed during a long period of coevolution. The reasons
for the host shift are unclear. Most likely this shift occurred when A. mellifera colonies were
transported to eastern Russia or the Far East in the ﬁrst half of the past century which led to a
sympatric distribution of both honey bee species and might have allowed the parasite to infest the
new host. Mites of Korean haplotype parasitise A. mellifera worldwide, including Europe. At least six
other haplotypes have been described. V. destructor is closely linked to its honey bee host and lacks a
free-living stage. There are two distinct phases in the life cycle of V. destructor females: a phoretic phase
on adult bees and a reproductive phase within the sealed drone and worker brood cells (Figure 1). Males
and nymph stages of the mite are short lived and can only be found within the sealed brood cells. On the
adult bees, the Varroa females are transported to brood cells for their reproduction or spread by foraging
and swarming bees. On the adult bees, the Varroa female usually is hidden under the sternites of the
1 V. destructor species was proposed recently (Anderson and Trueman, 2000), before it was known as V. jacobsoni.
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bee. The mites suck substantial amounts of haemolymph from both the adult bees and from the pre-
imaginal host stages within the sealed brood cells (Rosenkranz et al., 2010).
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
To date in Europe, there have been no reported naturally susceptible wildlife species to V. destructor.
Bumble bees and solitary bees have been the subject of many studies assessing parasitic and
infectious agents in the wild. None have reported the presence of V. destructor (OIE, 2008).
In Asia, some bee species (genus Apis) are susceptible to the mite (Rosenkranz et al., 2010).
Parameter 2 – Naturally susceptible domestic species (or family/orders)
In Europe, A. mellifera is the only susceptible domestic species (Table 1). A. cerana, the Asiatic
honey bee, a domestic bee not present in Europe, is also susceptible to Varroa, although, being
coevolved with the parasite, it appears to have some defence mechanisms that control the mite
infestation.
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
To date, no wildlife species have been experimentally shown to be susceptible to V. destructor.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
To date, no domestic species (apart from A. mellifera and A. cerana) have been experimentally
shown to be susceptible to V. destructor.
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
In Europe, there is no wild reservoir species. In Asia, wild bees are considered a reservoir for
V. destructor (Rosenkranz et al., 2010; Roberts et al., 2015).
Figure 1: Life cycle of V. destructor in a honeybee colony; Annual Review of Entomology® (Nazzi and
Le Conte, 2016)
Table 1: Domestic species naturally susceptible to V. destructor in Europe
Species Family Order
Apis mellifera Apidae Hymenoptera
AHL assessment on varroosis
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Parameter 6 – Domestic reservoir species (or family/orders)
In Europe, A. mellifera is the only reservoir of V. destructor. In Asia, other Apis species (e.g.
A. cerana, Apis nigrocincta) act as reservoir for Varroa spp.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/Incidence
Mite presence in colonies
If the colonies are not located in free zones, the prevalence of mites in honeybee colonies is
virtually 100% as all colonies host mites. There might be temporary mite-free colonies as a
consequence of intensive or ‘overdosed’ treatment activities.
Given the high rate of prevalence, it is difﬁcult to calculate any rates of incidence. An experiment has
been run in Germany to assess the re-infestation rates in speciﬁc conditions. It has shown that all colonies
of this experiment have been continuously infested with Varroa mites throughout the whole period of the
experiment despite continuous treatments in one of the modalities (Frey and Rosenkranz, 2014).
Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
The difﬁculty with varroosis is to establish thresholds for clinical signs. Honey bees are a so-called
superorganism where clinical symptoms in some individuals can be buffered at the colony level to a
certain point by the huge amount of still healthy bees and brood.
The ectoparasite mite V. destructor impairs both brood and adult bees causing a non-uniform
disease pattern called varroosis or parasitic mite syndrome and including a speciﬁc form of brood
damage termed ‘snotty brood’. The symptoms of varroosis are dependent on the rate of mite
infestation of a given colony and on viral infections vectored to individual bees by the parasitising
mites. Infested colonies in temperate climates will eventually die within around 2 years after the initial
infestation if left untreated. Varroosis inﬂicts much greater damage and higher economic costs than all
other known bee diseases (Genersch et al., 2010).
Very few surveys have documented the incidence of varroosis in European countries. The last
updated ﬁgures were produced by the EPILOBEE programme. Clinical prevalence of varroosis in the
apiaries were recorded during 2 years (2012–2014) in 17 Member States (MSs) of the European Union
(EU) and ranged between 0% and 52.6% (Laurent et al., 2016).
Mortality
Parameter 3 – Case-fatality rate
It is very difﬁcult to assess how many colonies die because of V. destructor. However, most of
epidemiological programmes assessing honeybee colonies mortalities underline the predominant role of
the mite in colony mortalities as it was stated in Germany (the average Varroa infestation level in
percentage in surviving colonies (av.  s.e.: 3.4  0.1) as signiﬁcantly lower than in lost colonies
(av.  s.e.: 15.1  0.7) (Genersch et al., 2010; Laurent et al., 2016); in Europe (Jacques et al., 2016,
2017), in Argentina (where colonies with treatment failure had 4.9 times more risk of mortality when
the percentage of Varroa infestation prior to treatment was more than 3% (Giacobino et al., 2014) or
in the US (Traynor et al., 2016). In temperate climate, colony mortality mainly occurs in late autumn or
during winter due to the damage of winter bees in highly infested colonies.
The bees’ behaviour can modulate the severity of infestation by the so called sensitive hygiene
behaviour, which involves the detection and removal of brood parasitised by Varroa (Mondet et al.,
2015).
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
Varroosis is not a zoonotic disease.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
V. destructor is treated with acaricidal active ingredients that include pharmaceutical chemicals,
essential oils or organic acids. The effect of the acaricides on V. destructor has been studied by means
AHL assessment on varroosis
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of different bioassays. Here, we report only the study of mite resistance towards acaricides. A prompt
detection of resistant Varroa population is vital to reduce the impact on bee losses and to test the
susceptibility of the Varroa mites to new varroacidal substances. Some bioassays have been used to
describe in the laboratory the resistance of Varroa to pyrethroids (tau-ﬂuvalinate, ﬂumethrin and
acrinatrine) of mite populations from Italy and more recently from Czech Republic but no ﬁgures are
available, e.g. on the percentage of population showing resistance (Milani, 1995; Kamler et al., 2016).
So far, no standard test system for a reliable and accurate quantiﬁcation of mite resistance to
acaricides is available (Dietemann et al., 2013). It should be said that ‘soft’ acaricides – organic acids
and essential oils have low probability of eliciting resistance after repeated treatments because they
are less speciﬁc, they are only used over short time periods, there are almost no residues for long-
term effects within the colony (Rosenkranz et al., 2010). The mechanism of action of ‘soft’ acaricides is
very different from synthetic acaricides, which target speciﬁc physiological (detoxifying enzymes)
processes that are highly regulated genetically.
In the ﬁeld, resistance to amitraz, ﬂuvalinate and coumaphos was also shown in Italy and the US
(Milani, 1999). Strains of Varroa mites resistant to one pyrethroid usually show cross-resistance with
other pyrethroids (Milani, 1999). Because several types of wax residues also may have some effect on
mites in the sealed cells, they are likely to create acaricide resistance, thus causing unrecognised
failure of control in the ﬁeld and serious damage to beekeeping (Rosenkranz et al., 2010).
In conclusion, given that acaricide treatments are applied worldwide to control Varroa mites,
resistances have appeared in different place of the world to different active ingredients. However,
when the active ingredient is not used for a while (only 1 year of alternative treatment is effective),
the frequency of the alleles for resistance declines rapidly (Gonzalez-Cabrera et al., 2013). This
characteristic is used in the management of acaricide resistance by rotating acaricides with different
active ingredients and ways of effect.
3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Given the nearly 100% prevalence of the Varroa mite in bee colonies in Europe, it is virtually
impossible to assess usual criteria of infectious diseases such as infectious period in the honeybee
colony, latent infection period, and the presence and duration of the mites in healthy carriers. Most
likely, all these characteristics might be very dependent on the environment, honeybee subspecies,
local beekeeper practices and climate (Meixner et al., 2015). In temperate climate regions, there is
usually a low Varroa infestation level in spring (if beekeepers have treated in autumn) and an increase
in mite population with, simultaneously, an increasing (re)invasion pressure. There is no place and
climate where Varroa disappears from the colonies and re-infects late in the season. Once Varroa is in
the colony, it stays the whole life of the colony. In the majority of cases, beekeepers have to treat
their colonies to avoid collapses due to varroosis. If beekeepers do not treat the honeybee colonies,
the collapse is expected within 2 years (Fries et al., 2006; Boecking and Genersch, 2008; Rosenkranz
et al., 2010).
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
V. destructor is closely linked to its honey bee host and lacks a free-living stage. V. destructor
cannot survive longer than a few hours without honeybee colonies as it is an obligatory parasite. It
cannot survive in soil, water or the open environment.
AHL assessment on varroosis
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3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
Adult female Varroa mites are transported horizontally from colony to colony via drifting by foraging
worker bees, vagrant drones and by robbing bees2 or even by moving infected frames that may act as
mechanical vectors. Vertical transmission takes place by swarming. In the new colony, introduced
Varroa mites at ﬁrst stay phoretically on the adult bees. The proliferation of the parasite occurs in the
capped brood cells of the honey bee. For this to occur, the female mite invades a cell just before
capping, preferring drone brood over worker brood (Boecking and Genersch, 2008).
Also, beekeeping practices can interfere with Varroa transmission as beekeepers can pass Varroa
from one colony to other relocating hives, frames or bees.3
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
There is no transmission of Varroa between honeybees and humans, since it is not a zoonotic
parasite.
Speed of transmission
The speed of transmission from colony to colony or from apiary to apiary has not been studied in
detail but very likely depends on the density of honey bee colonies and activities of beekeepers. For
instance, in case of translocation of honeybee colonies to target a special honey ﬂow, a free zone
(from Varroa) can be contaminated by infested colonies at a distance of hundreds of kilometres. In
Europe, given that very few areas free of Varroa exist, beekeepers often noticed the increase of Varroa
population in their colonies when the apiaries are located in zones where transhumance is dense, and
contaminated colonies are being brought by beekeepers. Once V. destructor has reached a country, it
has proved impossible to eradicate the parasite. Therefore, studies on transmission are rather difﬁcult
to run. Even in the recent introduction of the mite in Hawaii, no epidemiological study has followed the
dispersal of the mite (Martin et al., 2012). V. destructor is present in most areas of the EU with rare
exceptions. These sites free of mites are islands and remote valleys which give them speciﬁc
characteristics of small isolated places. If the mite is introduced in those places, the dissemination to
the entire territory will be quick and probably undetectable in the early stages.
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in the EU
V. destructor is present in all MSs of the EU with the exception of some islands and some remote
valleys (in Scotland for example). Ofﬁcially only two islands are recognised free of Varroa mites: the Isle
of Man and the Aland Island (Finland) (Commission Implementing Regulation (EU) No 485/20134).
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
V. destructor has been present in the western EU since the late 1970s (Rosenkranz et al., 2010)
and was detected earlier in some Eastern countries (Bulgaria, 1967). The mite is now endemic.
2 In regions with a high density of honey bee colonies, the population dynamics are inﬂuenced by a permanent exchange of
mites when foragers or drones enter foreign colonies or by robbing. Through this so called ‘reinfestation’, some colonies will
lose mites, and others will receive mites. It is interesting to note that the robbing bees will ‘receive’ the mites from the victim
colonies, which often are already weakened through a high Varroa infestation, and that the effective ‘robbing distance’ is more
than 1 km (Frey et al., 2011). This behaviour means that during periods with low nectar ﬂow and, therefore, high robbing
activities, strong colonies may signiﬁcantly increase their mite population (Rosenkranz et al., 2010).
3 Checking the presence of Varroa on a queen and its (maximum 20) attendants is possible before movement but it is practically
very difﬁcult to check for Varroa in a package of hundreds/thousands of bees.
4 Commission Implementing Regulation (EU) No 485/2013 of 24 May 2013 amending Implementing Regulation (EU) No 540/
2011, as regards the conditions of approval of the active substances clothianidin, thiamethoxam and imidacloprid, and
prohibiting the use and sale of seeds treated with plant protection products containing those active substances. OJ L 139,
25.5.2013, p. 12–26.
AHL assessment on varroosis
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Risk of introduction
V. destructor is already present in Europe.
3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
The OIE manual describes three methods to diagnose the presence of Varroa mites in colonies:
examination of honeybee colony debris, honeybee adults and honeybee brood (OIE, 2008).
Debris are collected at the bottom of honeybee colonies and are visually inspected to detect Varroa
(technically, molecular methods can be run on debris, but they are extremely expensive compared to
visual examination, and the quantiﬁcation (number of mites) is not as precise. Therefore, they are
never performed on a routine basis). Colonies can be equipped with meshed ﬂoors and bottom boards
are used to collect debris. In case of plain ﬂoors, dedicated panels can be inserted on the ﬂoor to
collect debris (Ryba et al., 2012). The collection duration varies depending on the conditions. Collection
of mites can be increased by the use of varroacides in the honeybee colonies. However, small or initial
infestations of a colony might not be detected by these methods, which suggests that an infection
level threshold must be exceeded before the detection of infection is possible.
Adults of honeybees (usually 300) can be sampled directly from the colony into a jar. To dislodge
mites from the bees, icing sugar, washing liquid or alcohol can be used. Subsequently the mites are
collected using a sieve. Various techniques are widely used and described in the literature (boxes, jars,
funnels or roofs of colonies can be used to collect adult honeybees).
The examination of brood, whether it is drone (male) brood or worker (female) brood involves
uncapping cells. Pupae removed from the cells are examined together with the cells and mite collected
(EFSA AHAW Panel, 2016).
Diagnostic of varroosis
Varroosis is mainly triggered by the viral infections transmitted and activated by the parasitising
mites. There is no clear consensus in the scientiﬁc community to describe the disease. Using the
techniques brieﬂy described above, various thresholds are provided in the literature to evaluate
varroosis. They depend on years, geographical zones and history of colony treatments and should,
according to recent publications, include prevalence and infection rates of honey bee viruses
transmitted by the mite (Kang et al., 2015; Giacobino et al., 2016; Wilfert et al., 2016).
The ﬁnal breakdown of a honey bee colony is associated with the typical ‘parasitic mite syndrome’
such as scattered brood, crawling or even crippled bees, supersedure of queens and unexplainable
reduction of the bee population (Rosenkranz et al., 2010).
Control tools
Parameter 2 – Existence of control tools
Concerning V. destructor there are no regulated measures at EU level to control the introduction or
the spread of the pathogen within the EU. However, national regulations can require treatment against
varroosis as, e.g. in Germany, France and the UK. The products that are used are listed in
Section 3.1.4.3 and their efﬁcacy depends on many factors, for instance beekeeping practices, climate
conditions (see details in Section 3.1.1.4). It is usually admitted that limiting the number of mites is
the best way against V. destructor using control methods with acaricides or zootechnical methods
(drone brood traps). Once the colony exhibits clinical signs (meaning that signiﬁcant numbers of mites
are present), it is unlikely that the colony can survive the winter. Without periodic treatment, most of
the honey bee colonies in temperate climates would collapse within a two 3-year period (Rosenkranz
et al., 2010). Therefore, Varroa control strategies have had to become an integral part of beekeeping
practice to keep infestation levels below the damage threshold for reducing colony losses caused by
this parasite.
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3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
The disease is present is all MSs with some rare local exceptions (see Section 3.1.1.7).
The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
It is very difﬁcult to assess the production losses due to either Varroa portage in colonies or
ongoing varroosis although it is widely acknowledged that varroosis is one of the main honey disease
reported worldwide (Chauzat et al., 2013; McMenamin and Genersch, 2015; Gisder and Genersch,
2017). The costs generated by Varroa presence in honeybee colonies have been estimated on honey
production in some conditions, but it is impossible to generalise to all types of productions (biological
beekeeping, beekeeping run in mountains, in forests, in ﬁeld crops). In France, the cost of three
Varroa mites per 100 bees has been estimated at a loss of 5 kg of honey on the lavender honey ﬂow
(Kretzchmar et al., 2016). Data were produced within the observatory for lavender honey ﬂow set up
in the south of France. The performance of 3,294 honeybee colonies was recorded between 2009 and
2016 in ﬁeld conditions. The gain of weight was regularly measured from the moment where the
beekeepers installed colonies in the ﬁeld to the honey harvest. The gain of weight is an integrative
variable that depends on the resources available for honeybees, the population of honeybees and the
sanitary state of the colonies. Varroa mites were systematically counted on living honeybees when
colonies were ﬁrst installed for lavender honey ﬂow. Results show that the gain of weight is around
23–24 kg for colonies that hosted between 0 and 3 mites per 100 bees. From the rate of 3 mites/100
bees, the gain of weight was systematically lower and negatively correlated with the number of mites:
The gain was around 21.3 kg for colonies hosting 3–5 mites/100 bees, and around 18.14 kg for
colonies hosting 5 mites to 8/100 bees. If not treated or badly treated, the honeybee colonies suffer
from varroosis or die. In the latter case, the production of bee products is lost.
Indirect agricultural losses due to colony weakening because of Varroa could be also linked to the
decrease in pollination service of honeybees in agricultural crops. The estimated value of insect
pollination in agriculture, including honeybees, is globally EUR 153 billion a year, almost a tenth of the
total value of world agricultural food production, and EUR 22 billion in Europe (European Commission,
2008), where the production of 84% of crop species cultivated depends directly on insect pollinators,
especially bees (Gallai et al., 2009). The contribution of honeybees to pollination is estimated to vary
considerably between different MSs, ranging from less than 25% (e.g. the UK, Finland) to more than
90% (e.g. Portugal, Ireland), depending on density of honeybees, temporal-spatial availability of hives
in relation to pollination demand and other factors (Breeze et al., 2014).
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
This is not applicable because there is no transmission of V. destructor between animals and
humans.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
In honeybees, the ability to express normal behaviour (e.g. feeding, orientation, communication,
ﬂight ability) and the health (e.g. decrease of normal weight, wing deformations), generally agreed as
components of welfare, are compromised by Varroa, leading in certain cases to the total collapse of
the colony. However, there is currently no speciﬁc deﬁnition of suffering in insects, and no means to
measure suffering.
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
All bee colonies in Europe (with rare exceptions, see above) host Varroa mites. When the parasitic
mite syndrome is observed in a colony, the survival of the colony without treatment is at risk during
the following winter. Varroa mites feed on larvae and adult bee haemolymph. They also transmit
viruses that cause physiological and physical alterations, such as wing deformations. One mite
decreases 7% of the weight of a single bee (De Jong et al., 1982) and between 11 and 19% in the
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case of drones (Duay et al., 2003), affecting ﬂight ability (Duay et al., 2002). Also, parasitised foraging
bees show less rates of returning to the colony and problems to get oriented (Kralj and Fuchs, 2006;
Kralj et al., 2007).
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
This is not applicable because there is no transmission of V. destructor to wild species in Europe.
The honey bee also provides pollination services to many wild plants, but the amount they
contribute compared to wild pollinators might be lower than previously acknowledged and even
pollination by managed honey bees supplements, rather than substitutes for, pollination by wild insects
(Potts et al., 2010; Garibaldi et al., 2013). Therefore, plant biodiversity loss due to decline in
pollination services by honeybees may not be signiﬁcant.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
Since Varroa is already present worldwide, the potential to generate a crisis situation is null.
Since Varroa is already present worldwide, the potential use of V. destructor as agroterrorism agent
is not relevant. It cannot be used for bioterrorism. The species is not listed in the bioterrorism lists.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
Varroosis is an OIE listed disease. The OIE manual describes three methods to diagnose the
presence of Varroa mites in colonies: examination of honeybee colony debris, honeybee adults and
honeybee brood – see Section 3.1.1.8 (OIE, 2008).
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
In Europe, there is only one species of Varroa mites hosted in honeybee colonies. The other free-
living mites present in colonies are pollen mites, which are not so frequent and morphologically
sufﬁciently different from Varroa mites to be easily distinguished. Therefore, the speciﬁcity of
diagnostic tests is considered high.
The sensitivity of tests has never been assessed and published with the exception of adult bee
samples in US (Lee et al., 2010). In this publication, the authors differentiate the needs in terms of
precision for beekeepers and researchers to evaluate Varroa population at apiary level. Researchers
can estimate apiary-level mite density by taking one 300-bee sample unit per colony, but should do so
from a variable number of colonies, depending on apiary size. An overview and detailed description of
the available diagnostic tools is given in Volume II of the COLOSS BeeBook (‘Standard’) (Dietemann
et al., 2013).
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
Matrices to be sampled, depending on the techniques applied are adult honeybees, worker brood,
drone brood or debris from the bottom of the hive by direct observation. Sampling debris from the
bottom of hive can be performed at any time of the year as it is a non-invasive technique (it is not
necessary to open the hive). Sampling adult honeybees is quite straightforward but needs the hive to
be open which means adequate temperature and climate. Sampling drone and worker brood is the
most destructive protocol and is dependent on the season (Dietemann et al., 2013).
3.1.4.2. Article 7(d)(ii) Vaccination
This is not applicable because no vaccination is available against V. destructor infection.
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3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
Over the last 20 years, the most noted synthetic acaricides against V. destructor are the
organophosphate coumaphos, the pyrethroids tau-ﬂuvalinate and ﬂumethrin as well as the
formamidine amitraz.
Most of these acaricides are easy to apply, economically convenient, and do not require reﬁned
knowledge of the mites’ biology. Veterinary treatments require a prescription from veterinarians.
Furthermore, as lipophilic substances they are mainly absorbed by the bees’ wax, thus not directly
jeopardising the honey. However, they are persistent and accumulate after repeated treatments
(Rosenkranz et al., 2010). Contamination of beeswax can have negative consequences on bee health
and on Varroa resistance (Collins et al., 2004; Medici et al., 2015). The European Medicines Agency
(EMA) hosts the Coordination Group for Mutual Recognition and Decentralised Procedures – Veterinary
(CMDv) that deals with the mutual recognition and decentralised procedure. The mutual recognition
within the EU is a procedure through which an authorisation of a medicine in one EU MS is recognised
by another MS. The CMDv released a document in 2015 listing all the treatments against Varroa
allowed in the EU (for instance Checkmite®, Perizin®, Apistan®, Apivar® and Bayvarol®) (EMA and
CMDv, 2015).
Organic acids and essential oils, namely formic acid, oxalic acid, lactic acid and thymol, represent
the frame of natural compounds used for the control of Varroosis. An enormous number of studies
have been conducted regarding the details of application under different climatic and beekeeping
conditions, i.e. concentration, time and number of treatments, method of application (powdering,
feeding, evaporating, fumigating, trickling or spraying) and others (Rosenkranz et al., 2010).
Parameter 2 – Availability/production capacity (per year)
The production of veterinary medicines is not limited in quantity. However, to overcome resistance
that mites have developed to the current active substances used to control varroosis, there is a need
for new acaricides to be developed by the industry (O’Brien et al., 2017), also a need to raise
awareness for the application of an integrated strategy for Varroa control together with a re-thinking
of agricultural techniques that may threaten or weaken bee colonies.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
Acaricide treatments are effective in the ﬁeld although some resistances have been already
described (see above). A summary of the different efﬁcacies and detected resistances tested in
different types of climate, breeding seasons of colonies is not available as ﬁgures are scattered in
different publications, thus requiring a meta-analysis of data. ‘Rotation’ in the use of different
acaricides within a ‘resistance management plan’ is a crucial recommendation; however, this might be
of limited effect due to the mainly non-professional structure of the beekeepers’ community. Therefore,
it is necessary to replace the often chemical-based Varroa control strategies with alternative methods
(Rosenkranz et al., 2010).
Feasibility
Parameter 4 – Way of administration
There is a large choice of veterinary medicines used in the EU to control V. destructor (although
they rely on a limited number of active substances, see above). The commercial formulations include
the use of strips to be inserted in the colonies, solutions applied by trickling, spraying, fumigating or as
pure crystals (e.g. sublimated with heat) without or with sugar, or in saturated absorbent blocks placed
over the brood combs. Mutinelli (2016) provides a summary of the information available on veterinary
medicines authorised in the EU and Switzerland.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
As it is not possible to prevent entry of Varroa in a colony, there are no biosecurity measures
speciﬁcally related to this disease. One basic measure would be to avoid relocation of frames from one
colony to another. Preventing swarming could also decrease Varroa spread by vertical transmission.
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3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Due to the route of transmission, restriction of the movement of bee colonies is not effective to
prevent the spread of Varroa. Restrictions on the movement of bee products are not relevant because
Varroa would only survive a few hours without living bees. The Commission Implementing Decision
2013/503/EU5 lays down free areas from varroosis in bees in the Union and establishes additional
guarantees for intra-Union trade and imports for the protection of their varroosis-free status. Within
EU, exchanges of colonies, packages of bees or queens are allowed provided they have a sanitary
certiﬁcate and that the exchange is registered in the European TRACE database.
3.1.4.6. Article 7(d)(vi) Killing of animals
Honeybee colonies should not be killed if Varroa mite presence is diagnosed in the colonies, instead
the colony should be treated.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
This is irrelevant for V. destructor for the same reasons as above (killing of animals).
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
The cost depends on the means used to control Varroa mites. Using medications is usually less time-
consuming. Control with biological treatments is more time-consuming as they imply several consecutive
treatments. The costs of the drugs whether they are chemicals or organic acids highly depend on the
national market. Control using zootechnical methods (queen encaging) is very time consuming, requires
technical skills from the beekeepers and can be at risk for the colony. Besides, the impact on the
production of beekeeping products is more severe when biological or zootechnical controls are used.
Therefore, the cost of control also depends on the MSs, since the price of medications ﬂuctuates
across countries. For an indication, the cost of chemical treatment is estimated at about EUR 4 to 10
for one colony. The price of one colony is estimated from EUR 80 to 150.
Data on the cost differentiated by the type of control (e.g. chemical, cultural, biological) are not
available.
Parameter 2 – Cost of eradication (culling, compensation)
This is irrelevant for V. destructor as eradication is not possible.
Parameter 3 – Cost of surveillance and monitoring
Eradication or control of spread being not possible, the surveillance of Varroa relies on counting the
mites or assessing the disease (varroosis). In 2011, the honeybee EURL sent a questionnaire to the
national reference laboratories (NRLs) of the 27 EU MSs as well as Kosovo and Norway. Some parts of
the questionnaire were dedicated to the surveillance of honeybee diseases. Varroosis with the
observation of clinical symptoms was included in 18 countries (Chauzat et al., 2013). The surveillance
or the monitoring plans for varroosis can have different goals: the evaluation of a threshold (beyond a
certain number of mites the colony is at risk), the evaluation of the treatments implemented at a
country level (do the beekeepers correctly treat their colonies? are the treatments effective?) and the
control of the disease (mandatory treatments beyond a threshold). The cost of such programs is linked
to services (human resources, equipment and consumables) needed for the collection of the
information (involvement of public or private veterinarians or beekeepers), the costs of the biological
analysis (involvement of the NRL or counting implemented by the beekeepers themselves), the data
storage and analysis (data bases need to be maintained, populated and data analysed) and the
animation of the network.
As example, some ﬁgures of the cost of surveillance are reported in some MSs. In the Czech
Republic, the quantitative laboratory examination of winter debris samples is used. The overall cost is
5 2013/503/EU: Commission Implementing Decision of 11 October 2013 recognising parts of the Union as free from varroosis in
bees and establishing additional guarantees required in intra-Union trade and imports for the protection of their varroosis-free
status. OJ L 273, 15.10.2013, p. 38–40.
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around EUR 54 000 per year that include 55,000–60,000 samples. In Italy, according to the BeeNet
project, using the sugar powder method, the costs were evaluated at EUR 50/apiary (10 colonies each).
The test was implemented once a year in September to 300 apiaries, leading to EUR 15,000/year. In
England and Wales, only an approximate global cost can be reported because different types of
surveillance were used, but data are not available for each. Every time a colony inspection is completed,
several observations are implemented (not speciﬁcally Varroa levels). The programme in England and
Wales runs at approximately EUR 2.0–2.2 millions per year (£1.8–£2 millions). This encompasses the
whole program from laboratory, ﬁeld, logistics and IT costs.
Parameter 4 – Trade loss (bans, embargoes, sanctions) by animal product
The bans on V. destructor at EU level are set by the Commission Implementing Decision 2013/503/
EU for regulating intra-Union trade and imports for the protection of varroosis-free areas. Introduction
bans of capped brood and adults into free areas are in place.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
Costs are induced by varroosis (veterinary products, working time for treatment) and losses (colony
collapse, reduced honey yields). However, given the different rates of varroosis observed across EU
and the high variability in costs related to treatment, labour and colonies, it is nearly impossible to
quantify losses in EUR at EU level.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
Destruction of hives because of the presence of V. destructor would not be accepted by the
population as it is totally irrelevant. Bans, embargoes or sanctions because of V. destructor would not
be accepted by the population either. The surveillance of V. destructor is well accepted in many EU
MSs.
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
Measures to reduce clinical signs of varroosis on honey bees can improve some components of
welfare of bee colonies (see Section 3.1.2.3). On the other hand, there is evidence that acaricide
treatment can potentially interfere with the health of individual honey bees and entire colonies
(Boncristiani et al., 2012; Adjlane et al., 2016; Garrido et al., 2016).
Parameter 2 – Wildlife depopulation as control measure
This is irrelevant for V. destructor as wildlife is not a reservoir of the disease.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
This is irrelevant for V. destructor as the veterinary treatments residues are located in beekeeping
matrices (honey, beeswax, propolis) that are not environmental compartments. The correct use of
chemical control products will not lead to contamination of the environment. A particular attention
should be provided for the disposal of veterinary products. Maximum residue limits have been set out
for two acaricides (Amitraz and Coumaphos) (Commission Regulation (EU) No 37/20106). A recent
publication studied the risk of chronic exposure of consumers to residues through the consumption of
contaminated honey and beeswax. The study concluded that the food consumption of honey and
beeswax contaminated with residues of plant protection products or veterinary substances considered
separately does not compromise the consumer’s health (Wilmart et al., 2016).
6 Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classiﬁcation
regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1–72.
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Biodiversity
Parameter 2 – Mortality in wild species
This is irrelevant for V. destructor as wildlife is not a reservoir of these mites and no data exist on
Varroa detection in feral colonies across the EU.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about varroosis (Table 2). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Table 3). The proportion of Y, N or na answers are reported, followed by
the list of different supporting views for each answer.
Table 2: Outcome of the expert judgement on the Article 5 criteria for varroosis
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
Y
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
N
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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Reasoning supporting the judgement
Supporting Yes:
• Multiple risk-mitigating measures such as zootechnical control and chemical treatments are
available and generally effective to control Varroa, even though not to eliminate it. These have
to become an integral part of beekeeping to maintain infestation levels below damage
thresholds and to reduce colony losses.
Supporting No:
• Risk-mitigating measures, although widely applied, are not totally effective, even if they are
well-applied, their efﬁcacy is variable, and varroosis is still considered one of the most
important factors for economic losses in the bee sector. Accuracy for treatments is also
needed. Biosecurity measures are not effective.
3.2.2. Outcome of the assessment of varroosis according to criteria of Article 5
(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 2, varroosis
does not comply with all criteria of the ﬁrst set because the assessment is inconclusive on compliance
with criterion 5 A(v). Therefore, it is inconclusive whether varroosis can be considered eligible to be
listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about varroosis (Tables 4, 5, 6, 7 and 8). The expert judgement
was based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 3: Outcome of the expert judgement related to criterion 5 A(v)
Question
Final
outcome
Response
Y (%) N (%) na (%)
A(v) Risk-mitigating measures and, where relevant,
surveillance of the disease are effective and
proportionate to the risks posed by the
disease in the Union
NC 67 33 0
NC: non-consensus; number of judges: 12.
Table 4: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for varroosis (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional
cases (irregular introductions) OR present only in a very limited part of the territory of the
Union
N
2.1 The disease is highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 the disease may result in high morbidity and signiﬁcant mortality rates Y
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At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
NC
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC), red = not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
Table 5: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for varroosis (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic
character AND (at the same time) several Member States or zones of the Union are
free of the disease
N
2.1 The disease is moderately to highly transmissible NC
2.2 There are possibilities of airborne or waterborne or vector-borne spread N
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic potential OR possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
4(PI) The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
Y
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets NC
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
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Table 6: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for varroosis (CI: current impact; PI: potential impact)
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character Y
2.1 The disease is moderately to highly transmissible NC
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality
AND often the most observed effect of the disease is production loss
N
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4(CI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
4(PI) The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related
to its direct impact on certain types of animal production systems
N
5(a)(CI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
5(a)(PI) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets NC
5(b)(CI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
5(b)(PI) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
na
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC), red = not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
5(c)(CI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(c)(PI) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d)(CI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
5(d)(PI) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC), red = not applicable (na), i.e. insufﬁcient evidence or
irrelevant to judge.
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3.3.1. Non-consensus-questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 9 and
10). The proportion of Y, N or ‘na’ answers is reported, followed by the list of different supporting
views for each answer.
Reasoning supporting the judgement
Supporting Yes for 2.1 (cat. A):
• In any Varroa-free area (na€ıve colonies) if the mite is introduced (e.g. even by one single
drone), the spread between and within the colonies will be highly effective, quick and initially
undetected and therefore difﬁcult to demonstrate how quickly the spread occurred to an
individual hive.
Supporting na for 2.1 (cat. A):
• There is limited scientiﬁc data to support high transmission.
Supporting Yes for 2.1 (cat. B, C):
• There might be high transmissibility in Varroa-free areas, but it is not always highly
transmissible because the speed of spread depends on the density of populations, mitigating
measures of bees and beekeepers as well as other factors.
• The rate of transmission within a colony varies depending on the colony’s development of
hygienic behaviour against Varroa.
• Varroa has spread to the entire Union in a few decades, which would conﬁrm at least
moderate transmissibility.
Table 9: Outcome of the expert judgement related to criterion 2.1 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.1 (cat. A) The disease is highly transmissible NC 33 59 8
2.1 (cat. B, C) The disease is moderately to highly transmissible NC 75 25 0
NC: non-consensus; number of judges: 12.
Table 7: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for varroosis
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
N
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL NC
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 8: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for varroosis
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL
and/or the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal
welfare, human health, the economy, society or the environment (If a disease fulﬁls the
criteria as in Article 5, thus being eligible to be listed, consequently category E would
apply.)
NC
Colour code: yellow = non-consensus (NC).
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Reasoning supporting the judgement
Supporting Yes:
• Beekeepers’ activity may be put at risk if losses of colonies are high.
• In the absence of controls, there could be substantial impact as a result of loss of pollination
services in agriculture.
Supporting No:
• It is already widespread across Europe and control measures are not always fully effective,
therefore the situation is not likely to become worse than the current one which is not of any
concern for the labour market.
3.3.2. Outcome of the assessment of criteria in Annex IV for varroosis for the
purpose of categorisation as in Article 9 of the AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 4–8. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
With respect to different type of impact where the assessment is divided into current and potential
impact, a criterion will be considered fulﬁlled if at least one of the two outcomes is ‘Y’ and, in case of
no ‘Y’, the assessment is inconclusive if at least one outcome is ‘NC’.
A description of the outcome of the assessment of criteria in Annex IV for varroosis for the purpose
of categorisation as in Article 9 of the AHL is presented in Table 11.
According to the assessment here performed, varroosis complies with the following criteria of the
Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a)–(e) of Article 9(1):
Table 10: Outcome of the expert judgement related to criterion 5(a)(PI) of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
5a The disease has a signiﬁcant impact on society, with in
particular an impact on labour markets
NC 92 8 0
NC: non-consensus; number of judges: 12.
Table 11: Outcome of the assessment of criteria in Annex IV for varroosis for the purpose of
categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment varroosis complies with criteria 2.3 and 2.4,
but not with criteria 1 and 2.2 and the assessment is inconclusive on compliance with
criterion 2.1. To be eligible for category A, a disease needs to comply additionally with one of
the criteria of the second set (3, 4, 5a–d) and varroosis complies with criterion 4, but not
with criteria 3, 5c and 5d, the assessment is inconclusive on compliance with criterion 5a and
not applicable on criterion 5b.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment varroosis complies with criterion 2.3, but not
with criteria 1, 2.2 and 2.4 and the assessment is inconclusive on compliance with criterion
2.1. To be eligible for category B, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and varroosis complies with criterion 4, but not with
criteria 3, 5c and 5d, the assessment is inconclusive on compliance with criterion 5a and not
applicable on criterion 5b.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment varroosis complies with criteria 1, 2.2 and 2.3,
but not with criterion 2.4 and the assessment is inconclusive on compliance with criterion
2.1. To be eligible for category C, a disease needs to comply additionally with one of the
criteria of the second set (3, 4, 5a–d) and varroosis does not comply with criteria 3, 4, 5c
and 5d, the assessment is inconclusive on compliance with criterion 5a and not applicable on
criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL, whose assessment performed is inconclusive for varroosis, and with
the speciﬁc criterion D of Section 4, with which varroosis does not comply.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating
to animal health, animal welfare, human health, the economy, society or the environment.
The latter is applicable if a disease fulﬁls the criteria as in Article 5 and the assessment here
performed for varroosis is inconclusive on compliance with the criteria as in Article 5.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
varroosis. The Article 8(3) criteria are about animal species to be listed, as it reads below:
‘3. Animal species or groups of animal species shall be added to this list if they are affected or if
they pose a risk for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.7 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for varroosis according to the criteria
of Article 8(3) of the AHL are as displayed in Table 12.
7 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, it is inconclusive whether varroosis can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
Eligibility of listing varroosis is dependent on a decision on criterion 5 A(v).
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, since it is inconclusive whether varroosis can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL,
then also the assessment of its compliance with each of the criteria in Annex IV to the AHL for
the purpose of categorisation of diseases in accordance with Article 9 of the AHL is
inconclusive.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list of
animal species that should be considered candidates for listing in accordance with Article 8 of the AHL.
• According to the assessment here performed, since it is inconclusive whether varroosis can be
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL,
then it is also inconclusive which animal species can be considered to be listed for varroosis
according to Article 8(3) of the AHL.
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Annex A – Mapped fact-sheet used in the individual judgement on
infestation with Varroa spp. (Varroosis)
Annex A can be found in the online version of this output (‘Supporting information’ section):
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